Semax: mechanism, Russian clinical evidence, and what the West hasn't replicated yet.
Semax is a heptapeptide derived from the ACTH(4–10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered by the Russian Ministry of Health in 1995. It has a real clinical literature and a genuine mechanistic story — and no published Western RCT data. Both facts matter equally.
- Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro; derived from ACTH(4–10), designed to preserve cognitive effects without the hormonal activity of full ACTH.
- Registered by the Russian Ministry of Health in 1995 for ischemic stroke and other neurological indications; used clinically in Russia intranasally at 0.1% and 1% concentrations.
- The strongest mechanistic claim is upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, supported by rodent hippocampal data (Dolotov et al., Brain Research 2006).
- Published Russian-language controlled trials exist for ischemic stroke outcomes (Uchakina et al. 2008; Myasoedov et al. 2001) — these are real, but their methodological detail is limited in translation.
- No peer-reviewed Western (non-Russian) randomised controlled trial of Semax has been published as of April 2026.
- Not FDA-approved, not EMA-approved. Sold in the US as a research chemical under RUO framing.
What Semax actually is
Adrenocorticotropic hormone (ACTH) is a 39-amino-acid pituitary hormone. Researchers in the 1970s noted that shorter fragments of ACTH — specifically the 4–10 sequence (Met-Glu-His-Phe-Pro-Gly-Lys) — retained the behavioural and neurotrophic properties attributed to the full molecule while losing the steroidogenic (cortisol-stimulating) activity that limits full ACTH's usefulness in chronic neurorehabilitation.
Semax is a synthetic modification of ACTH(4–10): the C-terminal lysine is replaced with a Pro-Gly-Pro extension (from the collagen-like tripeptide) that the Ashmarin group at Moscow State University showed improves stability and prolongs the neuroprotective effect profile. The resulting heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — is Semax. It has no ACTH receptor agonism, no steroidogenic activity, and no pituitary feedback effects at clinical doses.
The sequence is short enough to cross the blood-brain barrier via intranasal administration, which bypasses first-pass hepatic metabolism and allows direct CNS delivery through the olfactory and trigeminal nerve pathways. Intranasal PKin rodents and in Russian clinical formulations shows meaningful CNS distribution within 30–60 minutes of administration.
Mechanism: what the research supports
The mechanistic claims for Semax cluster around four effects seen in rodent models and to a lesser degree in Russian clinical studies:
- BDNF upregulation. The most replicated finding. Dolotov et al. (2006, Brain Research 1120:81–91, PMID 17010939) demonstrated increased BDNF mRNA and protein expression in rat hippocampus following Semax administration. TrkB receptor expression also increased. This is a mechanistically compelling finding: BDNF is a primary driver of synaptic plasticity, LTP, and neuronal survival, and reduced BDNF is implicated in depression, cognitive decline, and neurodegeneration.
- Dopaminergic modulation. Rodent studies from the Kozlovskaya group show Semax increases dopamine turnover in the striatum and prefrontal cortex — consistent with the attention-enhancement and working-memory effects reported in the Russian clinical literature. This also provides a mechanistic link to the Russian research use in attention-deficit presentations.
- Serotonergic effects. Moderate serotonergic modulation reported in some rodent models; proposed mechanism for the mild anxiolytic effects observed at lower doses in Russian practice.
- Anti-inflammatory and neuroprotective effects. Several Russian studies report reduced pro-inflammatory cytokine expression and reduced oxidative stress markers after ischemic challenge in rodents and in the Russian stroke clinical trials. The mechanism is not fully characterised at the molecular level.
The Russian clinical evidence
Semax has been used in Russian neurological practice since its Ministry of Health registration in 1995. Two types of clinical evidence exist:
Ischemic stroke studies. The primary registered indication. Myasoedov et al. (2001) published a controlled study in Zhurnal Nevrologii i Psikhiatrii reporting improved neurological deficit recovery in ischemic stroke patients receiving intranasal Semax versus standard care. Uchakina et al. (2008) reported immunomodulatory effects — specifically normalisation of cytokine profiles — in stroke patients. These papers represent real clinical programmes from credible researchers in the Russian neurological tradition.
Cognitive and attention studies. Russian-language reports (some summarised in Kozlovskaya et al. 2002, Uspekhi Fiziologicheskikh Nauk 33:3–21) describe benefits in attention deficit presentations and in non-pathological working memory tasks. The methodology in English summaries lacks detail on randomisation, blinding, and statistical handling.
N-Acetyl Semax Amidate — the modified variant
The research-chemical market offers N-Acetyl Semax Amidate (NA-Semax-A), which adds N-terminal acetylation and C-terminal amidation to the base Semax sequence. Vendors market these modifications as enhancing CNS penetration and prolonging the half-life by reducing enzymatic degradation. The chemistry rationale is sound: amidation at the C-terminus is a common stability-enhancement strategy for peptides subject to carboxypeptidase degradation.
However, the evidence base for the modified form is thinner than for base Semax. The Russian clinical literature uses base Semax in registered formulations; the NA variant is a research-chemical modification without its own registered clinical trial database. Researchers evaluating the modified form are extrapolating from base Semax data and from general peptide-chemistry principles. Our N-Acetyl Semax Amidate spoke covers this in detail.
Semax vs other cognitive peptides
| Compound | Mechanism class | Primary effect claimed | Human RCT evidence | Registry status |
|---|---|---|---|---|
| Semax | ACTH-analog / BDNF upregulator | Cognition, neuroprotection, attention | Russian Phase II–III (limited translation) | Russian MoH, 1995 |
| Selank | Tuftsin analog / GABA modulator | Anxiolysis, mild cognitive enhancement | Russian Phase II (limited translation) | Russian MoH, 2009 |
| Cerebrolysin | Neurotrophic factor concentrate | Neuroprotection, stroke rehab, Alzheimer's | Yes — multiple Phase III, Cochrane-reviewed | EMA (Austria, Germany, etc.) |
| Dihexa | MET receptor agonist | Memory enhancement (rodent) | No | None |
Semax occupies a specific niche: more evidenced than Dihexa, better mechanistically characterised than Selank, but not in the same evidentiary class as Cerebrolysin. For researchers comparing Semax head-to-head with Selank across all relevant dimensions, see our Semax vs Selank comparison spoke. For the focus-enhancement specific question, our peptides for focus spoke provides context across the full cluster. For the Semax-versus-stimulants comparison, our Semax vs modafinil analysis addresses the most commonly researched alternative.
Intranasal administration — pharmacokinetic notes
Semax's registered clinical formulations are intranasal drops — 0.1% solution (1 mg/mL) for cognitive indications and 1% solution (10 mg/mL) for stroke protocols. The intranasal route delivers the peptide via the olfactory epithelium to the olfactory bulb and from there via olfactory nerve axons and the trigeminal system to broader CNS regions, bypassing the blood-brain barrier. This route is pharmacokinetically superior to oral administration (which yields minimal intact-peptide bioavailability due to gastrointestinal protease activity) and avoids the injection requirement of subcutaneous or intravenous routes.
Research-chemical Semax is often supplied lyophilised and reconstituted in bacteriostatic saline by the end researcher. The 0.1% concentration corresponds to 1 mg per mL; researchers using nasal spray bottles (which typically deliver 0.1 mL per spray) would receive approximately 100 mcg per spray at this concentration. Our Semax intranasal dosing spoke covers concentration-calculation methodology in detail. Note that all dosing discussion on this platform is for research context only; Semax is not approved for human use in the United States.
Regulatory status
Semax is registered by the Russian Ministry of Health (registration number P N014948) and has been in clinical use in Russia since 1995. It is not approved by the FDA, EMA, or any Western regulatory body as a drug for any indication. In the United States, Semax is sold as a research chemical under a research-use-only framing — it is not legal for compounding pharmacies to prepare and dispense it for human use, and it is not a scheduled controlled substance (it has no abuse-potential schedule listing), which places it in a legal grey zone similar to other unscheduled research chemicals.
The absence of a US FDA IND application for Semax means there is no pathway for legitimate human clinical use in the US at present. Any vendor suggesting Semax is "approved" or "legal for human use" in the US is misrepresenting the regulatory situation.
Where to read further
Selected primary literature (PubMed-indexed where available):
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research. 2006; 1120(1):81–91. PMID: 17010939.
- Kozlovskaya MM, Andreeva LA, Myasoedov NF, Ashmarin IP. "Fundamental and applied aspects of the action of the regulatory peptide semax." Uspekhi Fiziologicheskikh Nauk. 2002; 33(1):3–21. [Russian]
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. "Immunomodulatory effects of semax in patients with ischemic stroke." Zhurnal Nevrologii i Psikhiatrii. 2008; 108(3):22–27. [Russian]
- Myasoedov NF, Skvortsova VI, Nasonov EL, Arakelyants AA. "Semax in the treatment of patients with ischemic stroke: a controlled randomized study." Zhurnal Nevrologii i Psikhiatrii. 2001; 101(6):28–30. [Russian]
- Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. "Design and investigation of a nonapeptide semax as an ACTH(4–10) analog without the side effects of hormonal peptides." Zhurnal Vysshei Nervnoi Deyatelnosti. 1995; 45(3):485–493. [Russian]